Clinical Trial: Comparison of Otezla to SFA-002 to Placebo in Plaque Psoriasis Patients

U.S., March 8 -- ClinicalTrials.gov registry received information related to the study (NCT06863493) titled 'Comparison of Otezla to SFA-002 to Placebo in Plaque Psoriasis Patients' on March 03.

Brief Summary: The goal of this clinical trial] is to learn if SFA002 can treat mild, moderate and severe plaque psoriasis as good or better than Otezla, compared to placebo in adult and pediatric patients.

The main questions it aims to answer are:

How much does oral SFA002 treatment improve plaque psoriasis measured at different timepoints, 12 weeks, 24 weeks and 52 weeks of treatment.

How much does Oral Otezla (Apremilast) improve plaque psoriasis measured at different timepoints, 12 weeks, 24 weeks and 52 weeks of treatment.

These treatments...